Across TCGA pan-cancer cohorts, IMP4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IMP4 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher IMP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IMP4 expression acts as an unfavorable survival marker.
ACC, UCEC, and SKCM are the cancer types where IMP4 Mutation most reproducibly stratifies survival.